Tolerability and safety of CBT101 for solid cancer patients
Unknown Phase 1 NCT04557306
Study Description
This study evaluates the safety and tolerability of CBT101 in patients with solid cancer who have undergone curative surgery and adjuvant therapy. CBT101 is an autologous natural killer cell used as a medical treatment.
Study Details
- Registry ID:
- NCT04557306
- Conditions:
- Solid Tumor
- Phase:
- Phase 1
- Target Enrollment:
- 6 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (1 site)
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, Korea, Republic of
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.